Tirzepatide vs. Semaglutide: Which Weight Loss Medication Is Right for You?

If you are comparing tirzepatide and semaglutide for weight loss, the question is no longer based only on separate clinical trials. We now have direct evidence comparing the medications under the same study protocol. The difference in average weight loss is important, but it is only one part of choosing a long-term treatment.

What Are Tirzepatide and Semaglutide?

Both are prescription medications that act on hormone pathways involved in appetite, food intake, glucose regulation and digestion.

They are related, but they are not the same medication and their doses are not interchangeable.

Semaglutide

Semaglutide is a GLP-1 receptor agonist. It mimics signaling from glucagon-like peptide-1, a hormone involved in appetite and glucose regulation.

Its effects include reduced appetite and food intake, increased feelings of fullness, glucose-dependent insulin secretion and delayed gastric emptying.

Wegovy is an FDA-approved semaglutide product for chronic weight management in qualifying patients. Current FDA labeling also includes reduction of major cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity.

Ozempic also contains semaglutide, but it is a separate product with diabetes-related FDA indications. Ozempic and Wegovy should not simply be used as interchangeable names for semaglutide weight-loss treatment.

Skin Works patients can review our semaglutide weight management program for current local treatment information.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates the glucose-dependent insulinotropic polypeptide receptor in addition to the GLP-1 receptor.

Zepbound is FDA-approved for chronic weight management in qualifying adults. It also has an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

Mounjaro also contains tirzepatide, but its FDA indication is for type 2 diabetes rather than chronic weight management.

For current local treatment information, see our tirzepatide weight management program.

How Do They Work Differently?

The most obvious pharmacologic difference is the number of receptor pathways involved.

Tirzepatide’s dual-receptor mechanism is pharmacologically different from semaglutide’s GLP-1 activity alone. But mechanism by itself does not tell us how much weight an individual patient will lose. Clinical outcomes are more useful than assuming “two hormones must be better than one.”

What Does the Head-to-Head Trial Show?

The SURMOUNT-5 trial directly compared weekly injectable tirzepatide with weekly injectable semaglutide in 751 adults with obesity who did not have type 2 diabetes.

Participants were treated for 72 weeks using the maximum tolerated dose of either tirzepatide, 10 mg or 15 mg, or semaglutide, 1.7 mg or 2.4 mg.

The difference in average weight reduction was statistically significant.

The most common adverse events in both groups were gastrointestinal, and most were mild to moderate. They occurred primarily during dose escalation.

Who Is Each Medication Best For?

There is no evidence-based rule that every first-time patient should start with semaglutide or that every patient wanting greater weight loss should automatically receive tirzepatide.

The decision should consider the full medical picture.

Semaglutide May Be Worth Discussing If You:

• are already responding well to semaglutide
• tolerate your current dose well
• have previously achieved meaningful weight reduction with the medication
• have established cardiovascular disease and may fit Wegovy’s cardiovascular-risk-reduction indication
• have medication-access or coverage circumstances that favor semaglutide

A higher average result from another drug is not, by itself, a reason to abandon a treatment that is safe, tolerated and working.

Tirzepatide May Be Worth Discussing If You:

• are seeking a treatment with greater average weight-loss efficacy in direct comparative evidence
• had an inadequate response to appropriately managed semaglutide treatment
• could not tolerate an effective semaglutide plan
• have obesity with moderate-to-severe obstructive sleep apnea and may fit Zepbound’s FDA-approved OSA indication
• have a medical history and treatment plan in which your prescriber believes tirzepatide is appropriate

Neither list replaces an individualized evaluation. Medical history, current medications, previous treatment, pregnancy plans, gastrointestinal health, diabetes status and long-term access all matter.

Safety and Side Effects

Both medications commonly cause gastrointestinal side effects, particularly during dose escalation.

Common effects can include:

• nausea
• diarrhea
• vomiting
• constipation
• abdominal discomfort
• indigestion or reflux
• reduced appetite

Side effects should not automatically be interpreted as evidence that the medication is “working harder.” Severe or persistent symptoms need medical attention and may require changing the dose or treatment plan.

Important Risks and Contraindications

Both Wegovy and Zepbound carry boxed warnings concerning thyroid C-cell tumors observed in rodents. It is not known whether these medications cause medullary thyroid carcinoma in humans.

Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other important risks or precautions can include:

• acute pancreatitis
• gallbladder disease
• kidney injury related to dehydration or volume depletion
• severe gastrointestinal adverse reactions
• hypoglycemia when used with insulin or certain diabetes medications
• diabetic retinopathy complications in patients with type 2 diabetes
• delayed gastric emptying
• potential aspiration risk during anesthesia or deep sedation

Current labeling does not recommend Wegovy or Zepbound in patients with severe gastroparesis.

Pregnancy and Contraception

Weight-loss treatment with either medication should be discontinued during pregnancy.

Current Wegovy labeling advises stopping semaglutide at least two months before a planned pregnancy because of its long half-life.

Zepbound should be discontinued when pregnancy is recognized.

Tirzepatide also has an important interaction consideration for patients using oral hormonal contraceptives. Current FDA labeling recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting Zepbound and for four weeks after each dose escalation.

Which One Works Faster?

The direct trial provides stronger evidence about the amount of weight lost over 72 weeks than it does about declaring a universal early “speed” winner.

Tirzepatide produced greater average weight reduction by week 72, but patients should not choose a medication based on whether the scale changes fastest during the first few weeks.

Both medications require gradual dose escalation. Early results can be influenced by:

• starting weight
• dose tolerance
• how quickly an effective maintenance dose is reached
• food intake
• physical activity
• other medications
• metabolic and medical conditions

Rapid weight loss is not automatically superior if side effects, inadequate nutrition or loss of strength make the treatment difficult to sustain.

What Happens If You Stop Semaglutide or Tirzepatide?

Obesity is a chronic disease, and these medications are generally studied as long-term treatments rather than short courses.

Weight regain after discontinuation is well documented.

In the STEP 1 extension, participants who had stopped semaglutide regained a substantial portion of the weight they had lost during treatment.

In the SURMOUNT-4 trial, participants first received tirzepatide and lost substantial weight. Those later switched to placebo regained weight, while participants who continued tirzepatide maintained and extended their reduction.

This does not mean every patient must remain on the same dose forever. It means that a maintenance plan should be discussed before treatment is viewed as “finished.”

What About Compounded Semaglutide or Tirzepatide?

This distinction matters.

FDA-approved products such as Wegovy and Zepbound have been reviewed by the FDA for their approved formulations, manufacturing, safety, effectiveness and labeling.

Compounded semaglutide and tirzepatide preparations are not FDA-approved drugs.

Compounding can be legally appropriate in certain circumstances when federal and state requirements are met and a specific patient need cannot appropriately be met by a commercially available product.

FDA rules restrict routine compounding of products that are essentially copies of commercially available FDA-approved drugs, and the regulatory environment around compounded GLP-1 medications has changed as national shortages have resolved.

Patients should know:

• the exact medication being prescribed
• whether the medication is FDA-approved or compounded
• which pharmacy dispenses it
• the concentration in the vial or delivery device
• the prescribed dose
• how that dose should be measured

This is particularly important with multi-dose vials, where concentration and syringe-unit errors can lead to incorrect dosing.

Current Skin Works Program Pricing

Skin Works currently offers provider-supervised injectable semaglutide and tirzepatide weight-management programs in Torrance.

Program cost increases with higher dose levels. These are Skin Works program prices and should not be interpreted as the retail cash prices of branded Wegovy or Zepbound.

How We Help You Succeed

Medication is only one part of a medical weight-management plan.

At Skin Works, treatment includes medical evaluation and ongoing follow-up rather than simply choosing a drug based on which one produces the largest average number in a study.

A responsible program should consider:

• medical history and medication eligibility
• weight and health goals
• dose response and tolerability
• nutrition and adequate protein intake
• resistance exercise when appropriate
• hydration and gastrointestinal tolerance
• changes in other health conditions or medications
• long-term maintenance planning

If you are comparing semaglutide with a different class of weight-loss medication, you may also find our Semaglutide vs. Phentermine comparison useful.

Final Thoughts: Tirzepatide vs. Semaglutide

Tirzepatide and semaglutide are both highly effective weight-management medications for appropriately selected patients.

The strongest current head-to-head evidence shows that tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without type 2 diabetes.

But “which medication causes more average weight loss?” and “which medication is right for me?” are not the same question.

The second question also requires considering safety, medical history, FDA-approved indications, side effects, treatment response, pregnancy plans, other medications, access, cost and the likelihood that treatment can be maintained.

Frequently Asked Questions